177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL). We aim to evaluate the efficacy and safety of and identify predictors of response to 177Lu-DOTATATE therapy in metastatic...

Full description

Bibliographic Details
Main Authors: Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar
Format: Article
Language:English
Published: Bioscientifica 2020-09-01
Series:Endocrine Connections
Subjects:
pheochromocytoma
paraganglioma
prrt
predictors of response
suvmax
Online Access:https://ec.bioscientifica.com/view/journals/ec/9/9/EC-20-0292.xml

Internet

https://ec.bioscientifica.com/view/journals/ec/9/9/EC-20-0292.xml

Similar Items